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Summary 
Intraperitoneal injection of pristane (2,6,10,14 tetramethylpentadecane) is a standard technique 
for obtaining monoclonal antibody-enriched ascitic fluid. However, pristane also induces plas- 
macytomas and an erosive arthritis resembling rheumatoid arthritis  in BALB/c mice, probably 
as a consequence of enhanced interleukin 6 production. We report here that the production of 
autoantibodies characteristic  of systemic lupus erythematosus  (SLE)  is a further  consequence 
of injecting pristane in BALB/c mice.  Anti-Su  antibodies appeared as early as  1-2 mo after a 
single injection of 0,5 ml pristane, followed by anti-U1RNP and anti-Sm antibodies after 2-4 too. 
Within 6 mo of pristane injection,  9 of 11 BALB/c mice had developed anti-Su,  anti-UIRNP, 
anti-U2RNP, anti-Sin, and possibly anti-U5RNP antibodies. Autoantibodies were not produced 
by 20 BALB/c mice of the same age and sex that were not injected with pristane.  Thus,  auto- 
antibodies characteristic  of lupus were induced in mice that  are not usually considered to be 
genetically susceptible to the disease.  The induction  of autoantibodies  associated with SLE by 
pristane may be relevant to understanding the role of abnormal cytokine production in autoantibody 
production  and the pathogenesis of autoimmune disease.  Furthermore,  the induction of high 
titer autoantibodies by pristane dictates caution in the use of ascitic fluid as a source of monoclonal 
antibodies,  since the polyclonal autoantibodies induced by pristane may copurify with the monoclonal 
antibody secreted by an injected hybridoma. 
I 
ntraperitoneal administration of pristane (2,6,10,14 tetra- 
methylpentadecane) before the injection of hybridoma cells 
is a standard technique for obtaining ascitic fluid containing 
a high concentration of mAbs.  In addition to its effects on 
hybridoma cell growth, pristane-induced alterations in cytokine 
production have been implicated in the pathogenesis of plas- 
macytomas  (1-3)  and erosive arthritis resembling  rheuma- 
toid arthritis (4, 5). While characterizing  a slowly growing 
murine hybridoma secreting an IgM mAb, we observed that 
ascitic fluid from several pristane-primed  BALB/c mice in- 
jected with hybridoma cells contained polyclonal IgG autoan- 
tibodies to Su, U1RNP, U2RNP, and/or Sm. Further inves- 
tigation revealed that the autoantibodies were a consequence 
of pristane priming itself, and were unrelated to the hybridoma 
cells or their secreted monoclonal IgM. Thus, intraperitoneal 
injection of pristane induced lupus-like autoimmunity in a 
strain of mouse not usually thought to be prone to autoim- 
mune disease. 
Materials and Methods 
Cell Lines.  The K562 (human erythroleukemia) and L929 (mu- 
fine fibroblast) cell lines were obtained from the American Type 
Culture Collection  (ATCC;  RockviUe, MD) and maintained  in 
RPMI 1640 or MEM, respectively, supplemented with 9% FCS, 
L-glutamine, and penicillinAtreptomycin. 
Sera and mAbs.  Prototype human autoimmune sera containing 
anti-Su, anti-U1RNP, anti-Sin, or other specificities, were reported 
previously (6-8). Additional sera with anti-U1RNP/Sm antibodies 
were obtained from patients  with systemic lupus erythematosus 
(SLE) followed at  the University  of North  Carolina  Hospitals 
(Chapel Hill, NC) or the Keio University Hospital (Tokyo,  Japan). 
Murine  mAbs 2.73 (anti-U1-70K) (9), and 9A9 (anti-U1-A and 
U2-B") (10) were provided  by Dr.  Yoshihiko Takeda (Medical 
College  of Georgia,  Augusta,  GA) and Dr.  W.J.  van Venrooij 
(University of Nijmegen,  The Netherlands),  respectively, mAbs 
Y2 (anti-Sm B'/B and D) (11), 22G12 (anti-Sm B'/B) (12), and 
2G7 (anti-Sin-D) (13) were provided by Dr. Robert A. Eisenberg 
(University  of North Carolina). 
Pristane Priming.  6-8-wk-old female BALB/c ByJ mice were ob- 
tained from The Jackson Laboratory (Bar Harbor, ME) and main- 
tained at our animal facility. Eleven mice, ages 4-5 mo, received 
a single intraperitoneal injection of 0.5 ml of  pristane (Sigma Chem- 
ical Co., St. Louis, MO). Sera were collected every 4 wk from the 
tail vein. 20 age- and sex-matched BKLB/c ByJ mice that were not 
injected with pristane served as controls. 
Immunoprecipitation.  Immunoprecipitation  using  cell extract 
from K562 or L929 cells was performed as described previously 
(7, 8). Briefly, the cells were labeled for 14 h with [3SS]methio- 
nine/cysteine (25/xCi/ml), lysed in 0.5 M NaC1 NET/NP-40 buffer 
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NP-40), and the extract cleared by centrifugation.  Labeled cell ex- 
tract derived from 1.5  x  106 cells was incubated for 90 rain with 
4/~1 of mouse serum plus 12/~1  of  rabbit anti-mouse IgG (1 mg/ml), 
or with 5/zl of human serum, absorbed onto 15/~1 of packed pro- 
tein A-Sepharose beads. The beads were washed three times with 
0.5 M NaC1 NET/NP-40,  and once with NET buffer (150 mM 
NaC1, 2 mM EDTA, 50 mM Tris-HC1, pH 7.5), and immunopre- 
cipitated proteins  were analyzed by SDS-PAGE. 
Pulse Labeling and Immunopre@itation.  K562 cells were pulse- 
labeled for 6 min with [3SS]methionine/cysteine as described (7), 
and extract derived from 3  x  106 cells was immunoprecipitated 
as above with mAbs 2.73, 9A9, Y2, 22G12, or 2G7, human  au- 
toimmune  sera, or 4 #1 of sera from mice injected with pristane. 
Immunoprecipitates were washed three times with mixed micelle 
buffer (MMB, 50 mM Tris-HC1, pH 7.5, 150 mM NaC1, 2 mM 
EDTA, 0.25 M sucrose, 2.5% Triton X, 0.5% SDS) and once with 
NET,  and analyzed by SDS-PAGE. 
Immunoblotting of  Sera with Purified U1RNP Antigen.  U1RNP 
antigen was immunoaffanity purified from K562 cell extract as de- 
scribed (14), fractionated on a 12.5% SDS polyacrylamide gel, and 
transferred to a nitrocellulose membrane. Strips cut from the mem- 
brane were incubated for 90 min with 1:250 diluted ascitic fluid, 
1:3 diluted culture supernatant of mAbs 2.73, 9A9, Y2, or 2G7, 
or 1:250 diluted human or routine serum. After washing, the strips 
were incubated an additional 90 rain  with alkaline phosphatase- 
conjugated goat antibodies specific  for either murine or human IgG 
(Fisher Scientific, Norcross, GA) and developed as described previ- 
ously (6). 
Figure  1.  SDS-PAGE of 3sS-labeled proteins  immunoprecipitated  by 
sera of pristane-primed  mice. Extract from K562 cells labeled 14 h with 
[3SS]methionine/cysteine was immunoprecipitated  with 4/~1 of mouse sera 
obtained 5 mo after pristane injection, followed by washing with 0.5 M 
NaC1 NET/NP-40 as described in Materials and Methods. lmmunoprecipi- 
tates were analyzed on a 12.5%  SDS gel and autoradiographed.  U1 and 
Su lanes show immunoprecipitation  with prototype anti-UIRNP and anti- 
Su sera, respectively. Lanes 1-11 show immunoprecipitation  with sera from 
11 pristane-primed BALB/c mice. Lane C shows immunopredpitation  with 
serum from a mouse that was not injected with pristane. Positions of the 
U1 snRNP-specific A and C proteins, the Sm proteins B'/B, D, E/F, and 
G, and the 200- and 100/102-kD  Su-related proteins are indicated.  Posi- 
tions of  molecular weight standards in kilodaltons are shown on the right. 
Results 
Induction of Anti-Su  Antibodies by Pristane.  5  mo  after 
receiving a single intraperitoneal  injection  of pristane,  sera 
from 5/11 BALB/c ByJ mice immunoprecipitated  100/102- 
and 200-kD polypeptides from extracts of 3SS-labeled human 
K562 erythroleukemia  cells  (Fig.  1,  lanes  1, 2,  8,  10,  and 
I1).  As shown in Fig.  1, the 100/102- and 200-kD proteins 
comigrated with  the proteins  immunoprecipitated  by anti- 
Su prototype serum (6). The identity of the polypeptides with 
Su was confirmed by preclearing experiments  (not shown). 
The sera also formed a line of identity with human and mu- 
fine anti-Su reference sera in Ouchterlony double immuno- 
diffusion (not shown), and immunoprecipitated similar poly- 
peptides from murine L-929 cell extract.  Sera from control 
mice were negative (Fig.  1,  lane C).  Autoantibodies  to Su 
are strongly associated with the diagnosis of lupus in both 
humans and MRL/Ipr mice (15), suggesting that pristane in- 
duced the production of autoantibodies characteristic of SLE 
in BALB/c mice. That possibility was further supported by 
the detection of serum autoantibodies to the components of 
U1, U2, and U5 small nuclear ribonucleoproteins (snRNPs). 
Induction of Autoantibodies to UI,  U2, and U5 snRNPs by 
Pristane.  The  U  series  of snRNPs carry the  shared "Sm" 
proteins B'/B, D, E, F, and G that form a 6S core precursor 
particle common to U1, U2, U4-6, and U5 snRNPs (7,  8, 
16), as well as other proteins unique to individual snRNPs. 
The unique proteins of U1 snRNPs include U1-70K, U1-A, 
and U1-C (17). U2 snRNPs carry the unique proteins U2-A' 
and U2-B" (17,  18), and U5 snRNPs carry unique proteins 
of 200 and  205  kD  (doublet)  (19).  Antibodies  specific  for 
the unique proteins of U1, U2, and U5 snRNPs will be re- 
ferred to as anti-U1RNP,  anti-U2RNP,  and anti-U5RNP, 
respectively, whereas those recognizing  the shared compo- 
nents  B'/B,  D,  E,  F,  or G  will be referred  to as  anti-Sm. 
Five sera from mice injected with pristane immunoprecip- 
itated the polypeptides A, B'/B,  C, D, E, F, and G  typical 
of U1 snRNPs from extracts of cells labeled for 14 h  (Fig. 
1, lanes  I,  5, 6, 9, and 11). Like anti-Su,  autoantibodies to 
U1 snRNPs are strongly associated with SLE in humans (11, 
20) as well as mice (21-23).  Two sera also immunoprecipi- 
tated the 200/205-kD protein components of U5 snRNPs 
(19)  at  5 mo  (Fig.  1,  lanes 5  and  6,  arrowhead), and three 
additional  mice  developed  these  antibodies  at  6  mo  (not 
shown). 
The fine specificities  of the anti-snRNP antibodies in sera 
from pristane primed mice were investigated by pulse labeling 
and immunoprecipitation  (Fig. 2 A). This technique permits 
evaluation  of autoantibody  binding  to  newly  synthesized 
snRNP proteins before the assembly of mature snRNP par- 
ticles (7, 8). As expected, murine mAbs immunoprecipitated 
different subsets of snRNP polypeptides from extracts of 6-min 
pulse-labeled K562 cells. Although mAb 2.73 (Fig. 2 A, lane 
1) is specific for the U1-70K protein (9), it immunoprecipi- 
tated  U1-A and  an unidentified  28-kD  protein  after pulse 
labeling.  The U1-70K polypeptide is radiolabeled poorly (7), 
and was therefore not well visualized.  In  accordance with 
its specificity for U1-A and U2-B" (10), mAb 9A9 immuno- 
precipitated both of these proteins (U2-B" has similar mo- 
bility to Sm-B',  see Fig. 2, lane 2, arrowhead), but not U1-C 
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Immunoprecipitation of 6-min pulse-labeled cell extract.  K562 cells were 
pulse-hbeled with [3SS]methionine/cysteine  for 6 min, and extract was im- 
munoprecipitated  with mAbs 2.73,  9A9,  Y2, 22G12, and 2G7,  human 
autoimmune sera, or sera from mice injected with pristane. Immunoprecipi- 
tares were washed with MMB and analyzed on a 12.5% SDS-polyacrylamide 
gel. Immunoprecipitation of pulse-labded  K562 cell extract  with mAbs 
specific for snRNP components is shown in lanes I-5. Lane I, mAb 2.73 
(anti-U1-70K);  lane 2, mAb 9A9 (reactive with U1-A and U2-B" pro- 
teins); lane 3, mAb 22G12 (anti-Sin B'/B); lane 4, mAb Y2 (anti-Sm B'/B 
and D proteins);  lane 5, mAb 2G7 (anti-Sm-D).  Immunoprecipitation of 
pulse-labeled cell extract with human autoimmune sera is shown in lanes 
6 and 7. Lane 6, anti-U1RNP positive human serum; lane 7, anti-UIRNP 
plus  anti-Sm  positive  human  serum.  Immunoprecipitation using anti- 
UIRNP positive  sera from mice injected  5 mo previously with pristane 
is shown in lanes A-E. Lane F shows immunoprecipitation with serum 
from mouse A before pristane  was injected.  (B) Western blot analysis of 
sera using purified U1R.NP antigen.  U1RNP antigen was immunoaf~nity 
purified from K562 cell extract,  fractionated  on a 12.5% SDS polyacryl- 
amide gel, and transferred to a nitrocellulose  membrane.  Strips cut from 
the membrane  were incubated  with diluted  mAbs or human or murine 
sera as described  in Materials  and  Methods,  followed by alkaline phos- 
phatase-conjugated  goat antibodies  specific for either murine or human 
IgG. Lanes I-4, mAbs 2.73 (anti-U1-70K),  9A9 (anti-U1-A and U2-B'), 
Y2 (anti-Sm  B'/B and D), and 2G7  (anti-Sm-D),  respectively. Lanes 5 
and 6, human autoimmune sera with anti-U1RNP antibodies; lanes 7 and 
8,  human anti-Sm/U1RNP positive sera. NHS, normal human serum. 
or the Sm proteins B'/B, D, E, F, or G. The latter were im- 
munoprecipitated, as expected, by the anti-Sm mAbs 22G12 
(anti-Sm B'/B [12], Fig. 2, lane 3), Y2 (anti-Sm B'/B and 
D [11], Fig. 2, lane 4), and 2G7 (anti-Sm D [13], Fig. 2 lane 5). 
As shown previously (7),  human autoimmune sera con- 
taining anti-U1RNP antibodies immunoprecipitated exclu- 
sively the U1-A and U1-C polypeptides, whereas sera con- 
taining anti-Sm antibodies immunoprecipitated  the Sm B'/B, 
D, E, F, and G proteins as well as U1-A and U1-C (Fig. 2 
A, lanes 6 and 7, respectively). All sera from pristane primed 
mice that immunoprecipitated proteins A-G from 14 h la- 
beled cell extract immunoprecipitated U1-A from pulse la- 
beled cell extract (Fig. 2 A, lanes A-E), whereas serum from 
a control BALB/c mouse not injected with pristane was nega- 
tive (Fig. 2 A, lane F). One of the sera from a pristane primed 
mouse also immunoprecipitated U1-C (Fig.  2 A, lane D), 
and two immunoprecipitated  U2-B" (Fig. 2 A, compare lanes 
D and E with lane 2). None of the mouse sera immunopre- 
cipitated the Sm proteins D, E, F or G, and the single serum 
that immunoprecipitated  B'/B did so weakly (Fig. 2 A, lane 
A). The pattern displayed by sera from pristane primed mice 
was similar to that of anti-U1RNP mAbs 2.73 and 9A9 or 
human autoimmune sera containing anti-UIRNP antibodies, 
suggesting that U1RNP, and not the Sm core proteins, was 
the major target of anti-snRNP autoantibodies in these sera. 
This interpretation was confirmed  by Western blotting using 
af~nity U1  snRNPs (Fig.  2 B). 
In agreement with the pulse labeling experiments, the sera 
of mice injected with pristane showed reactivity by Western 
blotting with U1-A (4/5 sera strongly, and 1/5 weakly posi- 
tive). Reactivity with U1-70K (3/5 sera strongly, and 1/5 
weakly positive) was also apparent, whereas reactivity with 
Sm-B'/B was weak or absent (Fig.  2 B, lanes A-E).  None 
of the sera was reactive with Sm-D. IgG1,  IgG2a, IgG2b, 
and IgG3 autoantibodies were all detected by Western blot 
using isotype-specific second antibodies (not shown). In con- 
trast to the BALB/c mouse sera, human autoimmune sera 
containing anti-Sm antibodies exhibited strong reactivity with 
B'/B (Fig. 2 B, lanes 7-8) and D (Fig. 2 B, lane 7), whereas 
normal human serum was negative. As expected, murine mAb 
2.73 was reactive on blots with U1-70K (Fig. 2 B, lane 1), 
and 9A9 reacted with U1-A (Fig. 2 B, lane 2). Since af~nity- 
purified U1 snRNPs were used as antigen, reactivity of 9A9 
with U2-B" was not apparent, mAb Y2 showed strong reac- 
tivity with Sm-B'/B and weaker binding to Sm-D (Fig.  2 
B, lane 3), whereas 2G7 showed reactivity with D, but not 
B'/B.  Taken together, the pulse labeling and Western blot 
studies indicated that sera obtained from BALB/c mice 5 mo 
after a single pristane injection contained autoantibodies specific 
for components of U1 snRNPs (primarily the U1-70K and 
U1-A proteins) and U2  snlLNPs  (the U2-B" protein). 
Time Course of  Autoantibody Production.  Although arthritis 
Lanes A-E show immunoblot analysis of mouse sera obtained 5 mo after 
pristane  injection.  Lane F  shows immunoblot using serum from mouse 
A before pristane  was injected. 
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parably, indicating that the sera contained true autoantibodies 
to U  snRNPs and Su. 
Figure  3.  (A) Immunoprecipitation with serial  sera from pristane-primed 
mice. Serial serum  samples (4 #1) obtained  from two mice (mice A and 
B, respectively) before injecting pristane, and at 1, 2, 3, 4, and 5 mo after 
pristane was injected,  were tested by immunoprecipitating 14 h radiola- 
beled K562 cell extract. Positions of 100/102 and 200 kD Su antigens and 
U1-A, U1-C, and Sm proteins B'/B and D are indicated. Positions of mo- 
lecular weight standards are shown on the left. (B) Time of onset of anti- 
Su, anti-UIRNP, and anti-USKNP antibodies. Sen from 11 pristane-primed 
BALB/c mice were tested at monthly intervals for anti-Su, anti-U1RNP, 
and anti-USRNP antibodies by immunoprecipitation.  The percentage of 
sera positive for anti-Su (solid  diamonds), anti-U1RNP (open  squares), U5RNP 
(solid squares), or any of the three (open diamonds), over time is shown. 
occurs 4-6 mo after the injection of pristane (4, 5), examina- 
tion of the ascitic fluid of mice injected with hybridoma cells 
suggested that autoantibody production might commence 
earlier  than  that.  Thus,  the time course of autoantibody 
production by pristane primed mice was  investigated.  As 
shown in Fig. 3, anti-100/102 and 200 kD Su antibodies gener- 
ally appeared between 1 and 2 mo after pristane priming (Fig. 
3 A-B, solid diamonds), whereas anti-U1RNP antibodies ap- 
peared somewhat later, between 2 and 3 mo after priming 
(Fig. 3 B, open  squares). Autoantibodies that immunoprecipi- 
tated the characteristic  200/205-kD doublet of U5 snRNPs 
(e.g., Fig.  1, lane 5), appeared still later, after 4-6 mo (Fig. 
3 B, solid  squares). By 6 too, 9/11 pristane primed mice (82%) 
had developed anti-Su,  anti-U1RNP,  and/or anti-USRNP 
autoantibodies (5/11  anti-Su,  5/11  anti-UIRNP,  and 5/11 
anti-U5RNP) (Fig. 3 B, open diamonds). The U sntLNP and 
Su antigens from human K562 (Figs. 1-3) and murine L-929 
Discussion 
The induction of autoantibodies to Su,  U1-A, U1-7OK, 
U2-B",  and Sm-B'/B, all of which are associated with SLE, 
in BALB/c mice by pristane has several implications. First, 
the "spontaneous" production of these autoantibodies is not 
limited to autoimmune strains of mice, suggesting that en- 
vironmental factors may play a role in initiating anti-Su and 
anti-snRNP antibodies.  It is of interest that, as in pristane- 
primed BALB/c mice,  anti-U1-A  and anti-U1-70K  auto- 
antibodies are detected in the sera of MRL/Ipr mice with 
spontaneous autoimmune disease before other anti-snRNP 
antibodies appear  (22).  In view of the sequence  similarity 
and immunological  crossreactivity  of U1-70K and the retro- 
viral p30sas antigen (24),  it is possible that reactivation of 
an endogenous retrovirus as a consequence of pristane injec- 
tion (25) was responsible  for the early  generation of anti- 
U1-70K autoantibodies in the pristane-primed mice. How- 
ever, further studies will be needed to evaluate that possi- 
bility.  The later  development of anti-Sm  B'/B  and  anti- 
U5RNP antibodies in some of the pristane-primed mice may 
reflect intermolecular/intrastructural diversification of the im- 
mune response to these snRNPs, as suggested previously (23). 
Thus, the production of autoantibodies after injecting BALB/c 
mice with pristane resembles spontaneous autoantibody pro- 
duction in MtLL/l/n'mice  in several  respects. We have observed 
recently that BALB/c mice develop  significant  proteinuria 
within several months after pristane injection, suggesting that 
similarity between the pristane model and spontaneous auto- 
immunity in MRL/Ipr mice includes the development of 
glomerulonephritis. 
In addition to their relevance to the pathogenesis of au- 
toimmunity, the present observations have broader significance 
relating to the commonly  used technique of producing mAbs 
in pristane-primed BALB/c mice (26).  In view of the rapid 
appearance of anti-Su antibodies after pristane injection, mAbs 
isolated from the ascitic fluid of pristane-primed mice injected 
with hybridoma cells may be contaminated by considerable 
amounts of polyclonal IgG autoantibodies. The possibility 
of autoantibody contamination of ascitic fluid will need to 
be taken into account, especially in the case of slowly growing 
hybridomas. We found that ascitic fluid from mice injected 
with a slowly growing IgM secreting hybridoma contained 
anti-Su antibodies of the IgG1, IgG2a, IgG2b, and IgG3 iso- 
types, and evidence of similar contamination of other mAbs 
prepared from ascitic fluid at other institutions has been found 
(data not shown). Purification of mAbs from culture super- 
natants should be considered to avoid this problem. 
The practice of growing hybridomas as ascites tumors in 
pristane-primed mice (26) is based on the observation that 
pristane, a common  component of many mineral oils, is plas- 
macytomagenic in susceptible  strains  of mice and enhances 
the ease of transplanting these tumors (1). Pristane is a peri- 
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matory response characterized by high levels of IL-6 produc- 
tion (27). Plasmacytomas arise in the off-induced granulomas 
after several months, and their frequency is increased by mul- 
tiple injections of pristane.  IL-6 produced by the macrophages 
and other cells within the oil-induced granulomas is an es- 
sential growth factor for plasmacytomas and is thought  to 
be instrumental  to the pathogenesis of these tumors (2, 27, 
28). In addition to enhancing the growth of plasmacytomas 
and the production of mAb enriched ascitic fluid, pristane 
has other effects, including the reactivation of endogenous 
retroviruses (25) and the development of erosive arthritis  resem- 
bling rheumatoid arthritis, accompanied by rheumatoid factor 
and autoantibodies to type II collagen (4, 5). These effects 
are not seen until 4-6 mo after pristane injection, and gener- 
ally require multiple pristane injections. Unlike the develop- 
ment of plasmacytomas and arthritis,  and the release of in- 
fectious  murine  leukemia  viruses  (25),  the  production  of 
autoantibodies typical of SLE was an early effect of pristane, 
seen as early as  1-2 mo after a single dose. 
Although the mechanism of autoantibody production in 
pristane-primed  BALB/c mice is uncertain,  overproduction 
of IL-6, which has been reported in these mice (27), is as- 
sociated with both autoantibody production and autoimmune 
disease  (29).  IL-6 transgenic  mice develop IgG1 plasmacy- 
toffs, hypergammaglobulinemia,  and mesangioproliferative 
glomerulonephritis (28). Moreover, SLE B cells secrete high 
levels oflL-6 spontaneously (30), and tumors that overproduce 
IL-6,  such as atrial  myxomas,  are associated with autoirfi- 
mune phenomena (29). Thus, there is considerable evidence 
for a link between IL-6 overproduction and autoimmunity. 
Although  it remains  to be shown that  IL-6 is involved in 
the  pathogenesis  of pristane-induced  autoantibodies,  the 
present study indicates that "normal" mice can produce lupus 
autoantibodies when exposed to a substance known to en- 
hance the production of ILo6. Further investigation of the 
pathogenesis of autoantibodies typical of lupus and autoim- 
mune disease (e.g.,  nephritis)  in pristane primed mice may 
provide new insight  into  the causes of SLE. 
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